Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neladenoson bialanate dose-finding in chronic heart failure with reduced ejection fraction
2016-003839-38Phase 2Completed
- Sponsor
- Bayer
- Start
- Nov 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of neladenoson bialanate in heart failure with reduced ejection fraction (HFrEF) (4 arms), sponsored by Bayer. Primary endpoints: Absolute change from baseline in left ventricular ejection fraction and Change from baseline in log-transformed NT-proBNP. Started Nov 2016; status: completed.
02
Drugs
neladenoson bialanate
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on 2016-003839-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003839-38.